Literature DB >> 16498512

The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Thierry Charron1, Nafiseh Nili, Bradley H Strauss.   

Abstract

Percutaneous coronary intervention is the preferred revascularization approach for most patients with coronary artery disease. However, this strategy is limited by renarrowing of the vessel by neointimal hyperplasia within the stent lumen (in-stent restenosis). Vascular smooth muscle cell proliferation is a major component in this healing process. This process is mediated by multiple cytokines and growth factors, which share a common pathway in inducing cell proliferation: the cell cycle. The cell cycle is highly regulated by numerous mechanisms ensuring orderly and coordinated cell division. The present review discusses current concepts related to regulation of the cell cycle and new therapeutic options that target aspects of the cell cycle.

Entities:  

Mesh:

Year:  2006        PMID: 16498512      PMCID: PMC2780832          DOI: 10.1016/s0828-282x(06)70986-2

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  189 in total

1.  Role for cyclin A in the dependence of mitosis on completion of DNA replication.

Authors:  D H Walker; J L Maller
Journal:  Nature       Date:  1991-11-28       Impact factor: 49.962

2.  Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division.

Authors:  T Evans; E T Rosenthal; J Youngblom; D Distel; T Hunt
Journal:  Cell       Date:  1983-06       Impact factor: 41.582

3.  Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study.

Authors:  G S Mintz; J J Popma; A D Pichard; K M Kent; L F Satler; C Wong; M K Hong; J A Kovach; M B Leon
Journal:  Circulation       Date:  1996-07-01       Impact factor: 29.690

4.  Update on In-stent Restenosis.

Authors:  Magdi M. El-Omar; George Dangas; Ioannis Iakovou; Roxana Mehran
Journal:  Curr Interv Cardiol Rep       Date:  2001-11

5.  Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat.

Authors:  J Ruef; A S Meshel; Z Hu; C Horaist; C A Ballinger; L J Thompson; V D Subbarao; J A Dumont; C Patterson
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

6.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

Authors:  M J Mann; A D Whittemore; M C Donaldson; M Belkin; M S Conte; J F Polak; E J Orav; A Ehsan; G Dell'Acqua; V J Dzau
Journal:  Lancet       Date:  1999-10-30       Impact factor: 79.321

7.  Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells.

Authors:  A Khanna; V Cairns; J D Hosenpud
Journal:  Transplantation       Date:  1999-02-27       Impact factor: 4.939

8.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.

Authors:  R Kornowski; M K Hong; F O Tio; O Bramwell; H Wu; M B Leon
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

9.  Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model.

Authors:  Gishel New; Jeffrey W Moses; Gary S Roubin; Martin B Leon; Antonio Colombo; Sriram S Iyer; Fermin O Tio; Roxana Mehran; Nicholas Kipshidze
Journal:  Catheter Cardiovasc Interv       Date:  2002-10       Impact factor: 2.692

10.  First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial.

Authors:  Alexandre Abizaid; Mariano Albertal; Marco A Costa; Andrea S Abizaid; Rodolfo Staico; Fausto Feres; Luiz A Mattos; Amanda G M R Sousa; Jeffrey Moses; Nicholas Kipshidize; Gary S Roubin; Roxana Mehran; Gishel New; Martin B Leon; J Eduardo Sousa
Journal:  J Am Coll Cardiol       Date:  2004-03-17       Impact factor: 24.094

View more
  5 in total

1.  Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2.

Authors:  Hua Liao; Junrong Gong; Wenjuan Zhang; Xiaomei Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

Review 2.  The COP9 signalosome and vascular function: intriguing possibilities?

Authors:  Douglas S Martin; Xuejun Wang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

3.  Arterial territory-specific phosphorylated retinoblastoma protein species and CDK2 promote differences in the vascular smooth muscle cell response to mitogens.

Authors:  Martin Lange; Tatsuya Fujikawa; Anna Koulova; Sona Kang; Michael J Griffin; Antonio D Lassaletta; Anna Erat; Edda Tobiasch; Cesario Bianchi; Nassrene Elmadhun; Frank W Sellke; Anny Usheva
Journal:  Cell Cycle       Date:  2013-11-12       Impact factor: 4.534

4.  Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats.

Authors:  Dun-Quan Xu; Ying Luo; Yi Liu; Jing Wang; Bo Zhang; Min Xu; Yan-Xia Wang; Hai-Ying Dong; Ming-Qing Dong; Peng-Tao Zhao; Wen Niu; Man-Ling Liu; Yu-Qi Gao; Zhi-Chao Li
Journal:  Respir Res       Date:  2010-12-24

5.  Shared genetic architecture between neuroticism, coronary artery disease and cardiovascular risk factors.

Authors:  Kristin Torgersen; Shahram Bahrami; Oleksandr Frei; Alexey Shadrin; Kevin S O' Connell; Olav B Smeland; John Munkhaugen; Srdjan Djurovic; Toril Dammen; Ole A Andreassen
Journal:  Transl Psychiatry       Date:  2021-06-17       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.